Latest Breaking News On - Nj novartis pharmaceuticals corporation - Page 1 : comparemela.com

Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups

Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2-.

San antonioUnited statesFrance generalComunidad autonoma de catalunaFran viscoDennisj slamonPrnewswire novartisShreeram aradhyeJonsson comprehensive cancer centerEuropean society for medical oncologyAmerican society of clinical oncologyNational breast cancer coalitionDrug administrationGlobal drug developmentExchange commissionAkershus university hospital

Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis

The ALITHIOS open-label extension study showed continuous treatment with Kesimpta® (ofatumumab) for up to five years in relapsing multiple sclerosis (RMS).

United statesCity ofUnited kingdomWallstroeme ofatumumabSloan simpsonJeffreya cohenPrnewswire novartisJulie masowMarlena abdinoorAmerican academy of neurologyNovartis pharmaceuticals corporationExchange commissionNational ms societyNovartis pharmaceuticals corpNeurological institute at cleveland clinicNj novartis pharmaceuticals corporation

Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer

Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting1 NATALEE is the.

United statesSan antonioFrance generalBasse normandieComunidad autonoma de catalunaSloan simpsonShreeram aradhyeDennisj slamonMarlena abdinoorMichael meoJulie masowMary carmichaelPfizer incGlobal drug developmentEuropean society of medical oncology congressEuropean commission

Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy

RIGHT Choice Phase II trial is the first randomized study in patients with aggressive HR+/HER2− metastatic breast cancer (MBC), including visceral crisis,.

United statesSan antonioNew jerseyComunidad autonoma de catalunaEast hanoverJeff legosYen shen luJulie masowMichael meoSloan simpsonMary carmichaelPrnewswire novartisAmerican society of clinical oncologyEuropean society of medical oncologyVestre viken hospitalTranslational research in oncology

Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy

Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesSan antonioNew jerseyComunidad autonoma de catalunaEast hanoverJeff legosYen shen luJulie masowMichael meoSloan simpsonMary carmichaelPrnewswire novartisAmerican society of clinical oncologyEuropean society of medical oncologyVestre viken hospitalTranslational research in oncology